European AI Drug Discovery Attracting Tech Investor Bets
Exscientia’s latest €434.9M ($525M) financing last month showed investors are still excited by efforts to…
14/05/2021 - 5 minutes
Trends & News
ADC Approval Buoys Spirits in Cancer Treatment Space
The FDA recently approved an antibody-drug conjugate drug from ADC Therapeutics as a treatment for…
11/05/2021 - 7 minutes
Despite Many Candidates, Covid-19 Treatments Lag Behind Vaccines
There’s promising early data on many potential Covid-19 treatments. Yet with vaccines in the spotlight,…
05/05/2021 - 5 minutes
Bluebird Bio Withdrawal Raises Gene Therapy Doubts in Europe
Last month, the US firm bluebird bio abandoned the sale of its gene therapy Zynteglo…
04/05/2021 - 5 minutes
BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel…
29/04/2021 - 5 minutes
EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls
While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations…
27/04/2021 - 6 minutes
Vazkepa Gets EMA Nod for Cardiovascular Disease, But Hurdles Remain
Last month’s EU approval of Vazkepa -- a treatment derived from fish oil and branded…
21/04/2021 - 5 minutes
Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions
The US medtech firm Hologic has bought the Finnish-French biotech Mobidiag for around €668M in…
20/04/2021 - 5 minutes
Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens
The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month…
15/04/2021 - 5 minutes
DBV Battles Aimmune for Share of Peanut Allergy Treatment Market
Last year, the FDA rejected DBV Technologies’ peanut allergy treatment and approved that of its…
14/04/2021 - 5 minutes
Artios-Novartis Pact Pushes Limits of DNA Repair in Cancer
A €1.1B deal struck this week between Novartis and the UK-based company Artios Pharma forges…
08/04/2021 - 5 minutes
Have European Investors Missed the Exosome ‘Gold Rush’?
When Oxford-based Evox Therapeutics announced its €81.1M (£69.2M) Series C round in February, it signaled…
01/04/2021 - 5 minutes
